Hotspot cancer panels target regions of known cancer genes that have been well-characterized as mutational hotspots. The small target region size produces a high depth of sequencing coverage per run, even when multiplexing many samples together. As a result, hotspot cancer panels provide a cost-effective and efficient method for discovering rare somatic mutations, many of which have been identified as important cancer drivers.
In addition to our proprietary OncoGxOne™ Discovery cancer panels, which assesses a number of specific tumor types, GENEWIZ also uses the TruSeq® Amplicon Cancer Panel from Illumina that targets 48 genes by amplicon sequencing on the Illumina MiSeq®, as well as the Ion AmpliSeq™ Cancer Hotspot Panel from Ion Torrent that targets 50 genes by amplicon sequencing on the Ion PGM™.
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
Azenta is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.